Business Description
Vor Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US9290332074
Share Class Description:
VOR: Ordinary SharesTotal Employee Number:
76Compare
Compare
Traded in other countries / regions
VOR.USA Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2021-02-05Description
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 162.02 | |||||
Equity-to-Asset | -0.42 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 32.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.51 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.59 | |||||
9-Day RSI | 47.77 | |||||
14-Day RSI | 53.29 | |||||
3-1 Month Momentum % | 33.24 | |||||
6-1 Month Momentum % | 29.53 | |||||
12-1 Month Momentum % | -50.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.15 | |||||
Quick Ratio | 19.15 | |||||
Cash Ratio | 18.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -127.2 | |||||
Shareholder Yield % | -3.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | Neg. Equity | |||||
ROA % | 171.19 | |||||
ROIC % | -1498.89 | |||||
3-Year ROIIC % | 458.27 | |||||
ROC (Joel Greenblatt) % | -5421.3 | |||||
ROCE % | -43.52 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 5.96 | |||||
Price-to-Owner-Earnings | 1.96 | |||||
EV-to-EBIT | -5.96 | |||||
EV-to-EBITDA | -5.96 | |||||
EV-to-FCF | -6.23 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.81 | |||||
Earnings Yield (Greenblatt) % | -16.78 | |||||
FCF Yield % | -10.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vor Biopharma Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -83.405 | ||
| Beta | 4.618 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 2.47 | ||
| Volatility % | 116.3 | ||
| 14-Day RSI | 53.29 | ||
| 14-Day ATR ($) | 1.244305 | ||
| 20-Day SMA ($) | 23.08825 | ||
| 12-1 Month Momentum % | -50.25 | ||
| 52-Week Range ($) | 6.5 - 49.95 | ||
| Shares Outstanding (Mil) | 59.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vor Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vor Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 76 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 23.37 (+0.09%) | ||
| General meeting for 2026 | 2026-06-11 09:00 | 13.00 (-0.38%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 13.66 (-4.87%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 16.47 (-4.24%) | ||
| Annual report for 2025 | 2026-03-30 | 14.48 (+6.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 14.48 (+6.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 09:50 | 15.44 (-2.03%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-13 10:30 | 14.15 (+0.35%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-02 14:30 | 7.68 (-7.80%) |
Show
Entries
Vor Biopharma Inc Frequently Asked Questions
What is Vor Biopharma Inc(VOR)'s stock price today?
The current price of VOR is $22.65. The 52 week high of VOR is $49.95 and 52 week low is $6.50.
When is next earnings date of Vor Biopharma Inc(VOR)?
The next earnings date of Vor Biopharma Inc(VOR) is 2026-11-13 Est..
Does Vor Biopharma Inc(VOR) pay dividends? If so, how much?
Vor Biopharma Inc(VOR) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases | 2022-03-22 |
Articles on Vor Biopharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers